CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, in mantle zone cells, and in scattered cells of the inter-follicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throughout B-cell development and through terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always negative, as are T-cell neoplasms.
200ug/ml of Ab Purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.
Antibody Type:
Monoclonal Antibody
Application Notes:
ELISA (For coating, order antibody without BSA), Flow Cytometry (1-2ug/million cells), Immunofluorescence (1-2ug/ml), Western Blot (1-2ug/ml), Optimal dilution for a specific application should be determined.
Flow cytometry of lymphocyte gated PBMCs stained with CD19 monoclonal antibody (PDR134) (red) or isotype control (gray) followed by goat anti-mouse CF640R (red).
* VAT and and shipping costs not included. Errors and price changes excepted
